1253114-37-2
Chemical Structure
Lpathomab
Synonym(s): LT3015; LT-3000
- CAS No.: 1253114-37-2
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Lpathomab]
Biological Activity: Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lpathomab | Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Visentin B, et al. Abstract# 1247: In vitro and in vivo efficacy of Lpathomab\# 8482;, a monoclonal antibody directed against lysophosphatidic acid (LPA), in ovarian cancer models[J]. Cancer Research, 2009, 69(9_Supplement): 1247-1247.
- [2]. Crack PJ, et al. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J Neuroinflammation. 2014 Feb 27;11:37. [Content Brief]
Keywords
